ReviewArthritis research & therapy2014
Immune checkpoint receptors in regulating immune reactivity in rheumatic disease.
Review in Arthritis research & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- The role and function of CTLA-4 in Sjögren's syndrome.Frontiers in immunology · 2026Review
- The role of PD-L1 gene silencing on growth, migration, and apoptosis in oral squamous carcinoma cell line HN-5.Annals of medicine and surgery (2012) · 2025Article
- Digital ischemia: a rare immune-related adverse event of immune checkpoint inhibitors-case report and review of the literature.Rheumatology international · 2024Review
- A Study on the Immunoregulatory Role of the PD1 Pathway in Juvenile Idiopathic Arthritis.Mediterranean journal of rheumatology · 2024Article
- Hydroxyproline metabolism enhances IFN-γ-induced PD-L1 expression and inhibits autophagic flux.Cell chemical biology · 2023Article
- Immune cellular patterns of distribution affect outcomes of patients with non-small cell lung cancer.Nature communications · 2023Article
- Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.Journal for immunotherapy of cancer · 2023Article
- Review
- Exploiting the role of T cells in the pathogenesis of Sjögren's syndrome for therapeutic treatment.Frontiers in immunology · 2022Review
- Magnetic Nanoparticles Used in Oncology.Materials (Basel, Switzerland) · 2021Review
- V-domain Ig suppressor of T cell activation (VISTA) inhibition is a new approach to cancer therapy: a Bibliometric study.Naunyn-Schmiedeberg's archives of pharmacology · 2021Review
- Real-world cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a retrospective controlled cohort study.American journal of cancer research · 2021Article
- T Cells Subsets in the Immunopathology and Treatment of Sjogren's Syndrome.Biomolecules · 2020Review
- Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?International journal of molecular sciences · 2020Review
- Elevated serum levels of checkpoint molecules in patients with adult Still's disease.Arthritis research & therapy · 2020Article
- Novel biomarkers for early targeted and individualized treatment in Juvenile Idiopathic Arthritis.Mediterranean journal of rheumatology · 2020Article
- Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.International journal of molecular sciences · 2020Review
- Co-inhibitory Receptor Signaling in T-Cell-Mediated Autoimmune Glomerulonephritis.Frontiers in medicine · 2020Review
- Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer.Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Immune checkpoint regulators are critical modulators of the immune system, allowing the initiation of a productive immune response and preventing the onset of autoimmunity. Co-inhibitory and co-stimulatory immune checkpoint receptors are required for full T-cell activation and effector functions such as the production of cytokines. In autoimmune rheumatic diseases, impaired tolerance leads to the development of diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome. Targeting the pathways of the inhibitory immune checkpoint molecules CD152 (cytotoxic T lymphocyte antigen-4) and CD279 (programmed death-1) in cancer shows robust anti-tumor responses and tumor regression. This observation suggests that, in autoimmune diseases, the converse strategy of engaging these molecules may alleviate inflammation owing to the success of abatacept (CD152-Ig) in rheumatoid arthritis patients. We review the preclinical and clinical developments in targeting immune checkpoint regulators in rheumatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.